Core Insights - Healthcare and life sciences enterprises are leveraging generative AI, agentic AI, and analytics to enhance patient care and streamline drug development [1] Group 1 - The integration of advanced AI technologies is transforming the operational landscape of healthcare and life sciences [1] - Generative AI is being utilized to improve patient outcomes and optimize the drug development process [1] - Analytics play a crucial role in supporting decision-making and enhancing efficiency within these sectors [1]

Core Insights - Healthcare and life sciences enterprises are leveraging generative AI, agentic AI, and analytics to enhance patient care and streamline drug development [1] Group 1 - Generative AI is being utilized to transform patient care [1] - Agentic AI is playing a significant role in drug development processes [1] - Analytics are increasingly integrated into healthcare strategies to improve outcomes [1]

Financial Performance - Total revenue reached $501 million, a 14.8% year-over-year (YoY) increase as reported and 15.1% on a constant currency (cc) basis[3] - Adjusted operating margin increased by 120 basis points (bps) YoY to 20.1%[3] - Adjusted diluted earnings per share (EPS) grew by 26.9% YoY to $0.48[3] Revenue by Segment (Q1 FY25) - International Growth Markets: $85.7 million, representing 17.1% of revenue, with 17% YoY cc growth[4] - Insurance: $172.1 million, representing 34.3% of revenue, with 8.7% YoY cc growth[4] - Healthcare and Life Sciences: $125.6 million, representing 25.1% of revenue, with 24.8% YoY cc growth[4] - Banking, Capital Markets and Diversified Industries: $117.7 million, representing 23.5% of revenue, with 14.3% YoY cc growth[4] Additional Metrics (Q1 FY25) - The company added 10 new clients[11] - Employee count reached 60,652, an increase of 1,100 from Q4 2024[11] - Attrition rate was 22.4%[11] - Data and AI-Led Revenue reached $267.9 million, representing 53.5% of revenue, with 16% YoY cc growth[11] - Digital Operations Revenue reached $233.1 million, representing 46.5% of revenue, with 14.2% YoY cc growth[11] FY25 Guidance - Revenue is projected to be between $2.035 billion and $2.065 billion[18] - Adjusted diluted earnings per share are projected to be between $1.83 and $1.89[18]